A large new multi-institution study led by Cleveland Clinic researchers adds to the body of evidence supporting the safety of biologics use prior to surgery for inflammatory bowel disease.
Biosimilar Safety and Efficacy Comparable to Biologic Treatment in IBD Patients
Biologic compounds have long been considered the gold standard immunosuppressive therapy for moderate-to-severe IBD, but growing evidence suggests that biosimilars offer similar benefits at a much lower cost. Now, a new Cleveland Clinic study comparing the biologic compound infliximab with the biosimilar infliximab-abda shows that the two therapies are comparable in both safety and efficacy
Impact of Biologics Use on Bone Loss in Patients with IBD
IBD patients treated with biologics are significantly less likely to have osteoporosis and bone fractures compared with those who did not, according to the largest individual study to date investigating the prevalence of osteoporosis and bone fractures in IBD patients with and without biologics therapy.
Cutaneous Adverse Effects of Surface-Targeted Monoclonal Antibodies
Biologic therapies, such as surface-targeted monoclonal antibodies, have revolutionized medicine and offer targeted therapy for an increasing number of diseases; however, along with these advances and their ensuing expanded use have come many unique adverse effects. In this article, dermatologists review how to manage these adverse effects and when to consult a dermatologist.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors
Biologic therapies, such as epidermal growth factor receptor inhibitors, have revolutionized medicine and offer targeted therapy for an increasing number of diseases; however, along with these advances and their ensuing expanded use have come many unique adverse effects. In this article, dermatologists review how to manage cutaneous adverse effects of EFGR inhibitors and when to consult a dermatologist.
Cutaneous Adverse Effects of Biologic Medications
Biologic therapies have revolutionized medicine and offer targeted therapy for an increasing number of diseases; however, along with these advances and their ensuing expanded use have come many unique adverse effects. In this series, dermatologists discuss management strategies for cutaneous adverse effects from biologics.
No. 6 Medical Innovation for 2020: Biologics in Orthopaedic Repair
Biologics in orthopaedic repair will be the No. 6 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
60-Second Sound-off: How Biologics Fundamentally Changed Clinical Immunology (Video)
Leonard H. Calabrese, DO, Director of the R.J. Fasenmyer Center for Clinical Immunology, explains in less than 60 seconds why rheumatologists are no longer satisfied with “small outcomes” for their patients.
Biologics Summit Continues to Grow
Physicians, scientists and advanced practice providers from virtually every medical specialty and scientific field heard their colleagues on the leading edge of this work highlight the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.
Breaking Down Biologic Use in Severe Asthma
The development and availability of biologic agents to target specific pathophysiological elements of severe asthma has altered the landscape of care. Our asthma experts break down biologic use for patients with severe asthma.